Acetazolamide

Acetazolamide
Product Description

Therapeutic Area: Cardiovascular systemEU DMF availableUS DMF no. 10383 availableCEP available Available also in injectable form Indication: Acetazolamide decreases the pressure in the eye and is used for adjunctive treatment of glaucoma, a condition in which increased pressure in the eye can lead to gradual loss of vision (chronic simple /open-angle/ glaucoma, secondary glaucoma, and preoperatively acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide is also used to reduce the severity and duration of symptoms (upset stomach, headache, shortness of breath, dizziness, drowsiness, and fatigue) of altitude (mountain) sickness. Acetazolamide is used with other medicines to reduce edema (excess fluid retention) and to help control seizures in certain types of epilepsy.

Read more Show less

Polpharma S.A.

  • PL
  • 2015
    On CPHI since
  • 4
    Certificates
  • 5000+
    Employees
Company types
CMO/CDMO
Contract Service
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
View company profile
Specifications
  • Supplied from
    Poland
More specifications Fewer specifications
Sales Markets
Show more Show less

Polpharma S.A.

  • PL
  • 2015
    On CPHI since
  • 4
    Certificates
  • 5000+
    Employees
Company types
CMO/CDMO
Contract Service
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
View company profile

More Products from Polpharma S.A. (34)

  • Isavuconazole sulfate

    Product Isavuconazole sulfate

    DISCLAIMER

    The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP...
  • Enzalutamide

    Product Enzalutamide

     We provide with Anhydrous form R1

    Enzalutamide is a second-generation androgen receptor inhibitor used to treat castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of c...
  • Isavuconazole

    Product Isavuconazole

    under development
  • Sacubitril Valsartan

    Product Sacubitril Valsartan

    Crystalline polymorphic form
    Sacubitril/valsartan is the first agent to be approved in a new class of drugs called angiotensin receptor neprilysin inhibitor (ARNI). The medication is FDA-approved to treat patients with chronic heart failure with reduced ejection fraction (HFrEF) with NYHA class I...
  • Ticagrelor, Form II

    Product Ticagrelor, Form II

    DISCLAIMER Each product is protected by a patent in force in Poland and is therefore developed and manufactured solely for the purpose of Regulatory Submissions or R&D purposes. This product is not offered for sale in countries where the patent is valid and the offer or sale or any relat...
  • Acenocoumarol

    Product Acenocoumarol

    Therapeutic Area: Cardiovascular systemEU DMF available Indication: Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist
  • Aripiprazole

    Product Aripiprazole

    Therapeutic Area: Nervous SystemEU DMF availableUS DMF no. 23314 availableCEP available Indication: used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression). It is also used together with other medications to treat major depressive disorder in adult...
  • Carbamazepine

    Product Carbamazepine

    Therapeutic Area: Nervous System EU DMF availableUS DMF no. 26266 availableCEP available Indication: Carbamazepine is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder, as well as trigeminal neuralgia.
  • Carvedilol

    Product Carvedilol

    Therapeutic Area: Cardiovascular systemEU DMF availableUS DMF no. 17060 availableCEP available Indication: Carvedilol is a carbazole derivative acts as anti-hypertensive agent. It is formulated as tablets for oral route of administration. Carvedilol is indicated for the management of essential hypertens...
  • Carvedilol phosphate hemihydrate

    Product Carvedilol phosphate hemihydrate

    Therapeutic area: Cardiovascular systemEU DMF availableUS DMF no. 20633 available
  • Clopamide

    Product Clopamide

    Therapeutic Area: Cardiovascular systemEU DMF available Indication: Clopamide is indicated for the treatment of oedema, hypertension. It is formulated as tablet for oral administration. It is categorised as a thiazide like drug and works in similar way as the thiazide diuretics. It acts at the proximal c...
  • Etodolac

    Product Etodolac

    Therapeutic Area: Musculo-skeletal systemEU DMF availableUS DMF no. 11405 availableJapanese DMF availableCEP available Indication: Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) used for the management of mild to moderate pain, fever, and inflammation.
show all 34 other products

Polpharma S.A. resources (10)

  • CPHI Barcelona 2023: Tackling the Pharma Talent Precipice – Part 2

    News CPHI Barcelona 2023: Tackling the Pharma Talent Precipice – Part 2

    This year at CPHI Barcelona (24–26 October, 2023) we sat down with C-suite executives and HR professionals to discuss the looming talent crisis in the pharmaceutical industry. With hybrid working persisting post-pandemic and a growing skills gap, how can the pharmaceutical supply chain adjust to a changing labour force? 
    15 Nov 2023
  • API Product List 2024

    Brochure API Product List 2024

    We manufacture our products by following our customers' and health authorities' most stringent requirements. DMF documentation for all our products is prepared in accordance with the latest requirements of EDQM (CEP), ICH (EuDMF, CTD), and FDA (US DMF). Material and product testing is performed in line with the European and United States Pharmacopeias.

  • News KiloLab Laboratory: strategic milestone achieved!

    KiloLab Laboratory – a development and production in a kilogram scale – has been launched, according to Polpharma API development strategy adopted in 2021.
    12 Oct 2023
  • POLPHARMA API: TECHNOLOGY EXPANSION & STRATEGIC DIRECTION

    Video POLPHARMA API: TECHNOLOGY EXPANSION & STRATEGIC DIRECTION

    Recent investments in Polpharma API’ capabilities will support a strategic move into complex API development and manufacturing for CDMO partners and generics companies worldwide, empowering the global supply chain.Visit us and learn how Polpharma API enters into a strategic transformation process that aims to invest in new capabilities and technologies like high containment or cryogenic to be fully implemented by 2026. However, our production capacity will increase significantly already from mid-2023!

    Would like to meet our representatives and learn more, please contact us today: [email protected]; [email protected]
    2022-10-10

  • News Polpharma’s strategic investment in HPAPI facility

    Polpharma’s strategic investment in HPAPI facility, the first of this kind in Poland and one of the most advanced in Central Easter Europe.

    19 Apr 2023
  • How can we grow business value together?

    Video How can we grow business value together?

    Check out how we can create business value together in the whole pharmaceutical value chain, including API, B2B, commercial partnerships and other forms of collaboration. In the video: Markus Sieger, CEO of Polpharma Group, David Gonzalez, Commercial Director of API Business Unit, Mieczyslaw Starkowicz, Head of B2B Venture and Simon Clark, Commercial Director for Polpharma Group and strategic partners.
    2022-10-10
  • Dossier List FDF Polpharma & Farmaprojects

    Brochure Dossier List FDF Polpharma & Farmaprojects

  • Polpharma & Farmaprojects FDF Dossier List

    Brochure Polpharma & Farmaprojects FDF Dossier List

    We offer an attractive portfolio of FDF focused on the newest and most prescribed therapies, having a customer centric approach through a multidisciplinary support team: Sales, Marketing, R&D, RA, QA&QC, IP, etc. Due to combined efforts of Polpharma and its strategic partner Farmaprojects we guarantee supply continuity in EU and non-EU territories.
  • Strategic investment HP API facility

    Video Strategic investment HP API facility

    In 2022, we are opening a new chapter in the history of Polpharma in the field of ​​active substances. With the strategic investment in a HPAPI facility, Polpharma and Poland are becoming a strong pillar of the European pharmaceutical industry in the coming decades.

    Grand opening of new R&D & Production Facility in Q3 2024

    Completion of this investment is scheduled for the first quarter of 2024. It will include separate process laboratories (PDL), analytical laboratories (ADL) with the possibility of performing Quality Control analyses, and a GMP kilo-lab production line with volume up to 1.5 kg with potential volume increase.

    Use link to read more: https://www.api.polpharma.com/news/polpharmas-strategic-investment-in-hpapi-facility-the-first-of-this-kind-in-poland/
    2024-08-06
  • Polpharma API CDMO offer

    Brochure Polpharma API CDMO offer

    Polpharma API CDMO (Contract Development and Manufacturing Organization) supports emerging and large pharmaceutical customers in the development and commercialization of their small-molecule APIs clinical candidates thanks to +70 years of experience in process development, scale-up, and cGMP manufacturing of small molecule APIs in volumes ranging from kilos to tens of tons.